Idiopathic Hypersomnia (IH) Treatment Market to Reach USD 835.2 Mn by 2035

According to analysts at Vantage Market Research, the Global Idiopathic Hypersomnia (IH) Treatment Market size is worth USD 340.4 Million in 2024 and is projected to reach USD 835.2 Million by 2035, growing at a CAGR (Compound Annual Growth Rate) of 8.5% from 2024 to 2035. Key trends of market include advancements in wakefulness-promoting agents, growing use of non-pharmacological therapies, rising awareness of IH, and increasing investment in sleep disorder research.

Market Overview

Idiopathic hypersomnia (IH) is a rare neurological sleep disorder characterized by excessive daytime sleepiness (EDS) despite prolonged nighttime sleep. Individuals with IH often sleep normal or extended hours at night yet continue to experience overwhelming drowsiness during the day. Symptoms may include unrefreshing naps, difficulty waking up (often referred to as sleep drunkenness), and persistent fatigue. The exact cause of idiopathic hypersomnia is unknown, and no treatments have been specifically approved by the U.S. FDA for this condition. However, medications like dextroamphetamine, which are approved for narcolepsy a related type of hypersomnia—are sometimes used off-label to manage IH symptoms.

The Idiopathic hypersomnia (IH) Treatment Market is being driven by several key factors, starting with the increasing awareness of sleep disorders and the growing recognition of idiopathic hypersomnia as a significant health issue. As awareness rises, more individuals are seeking diagnosis and treatment for excessive daytime sleepiness (EDS) and other related symptoms. This heightened awareness has led to greater emphasis on research and development in the field of sleep medicine, with a focus on improving diagnostic techniques and treatment options. Furthermore, lifestyle-related factors such as stress, anxiety, and irregular sleep patterns, which are linked to an increase in sleep disorders, are contributing to the growing demand for IH treatments.

NLS Pharma Receives Positive Opinion for Orphan Drug Designation of Mazindol ER (Quilience) for Idiopathic Hypersomnia Treatment

• In July 2022, NLS Pharma Ltd. announced that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMA) had provided a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) in the treatment of idiopathic hypersomnia (IH)

Key Takeaways from the Report

• In 2024, based on the Drug Class, the Stimulant Medications category accounted for significant market share of 53.5%. Stimulant Medications includes drugs like dextroamphetamine and modafinil, are commonly used to manage excessive daytime sleepiness (EDS) associated with IH
• North America dominated the Idiopathic hypersomnia (IH) Treatment market with 50.5% market share in 2024.  Market is driven by increased awareness and robust investment in research and development

Top Companies

• Merck & Co. Inc.
• Jazz Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• BIOPROJET
• Avadel Pharmaceuticals PIc. 
• GlaxoSmithKline plc
• Pfizer Inc.
• Theranexus
• Fisher & Paykel Healthcare Limited
• Drive DeVilbiss Healthcare LLC

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Avadel Pharmaceuticals Launches LUMRYZ for Cataplexy and Idiopathic Hypersomnia Treatment

• In August 2024, Avadel Pharmaceuticals plc, a biopharmaceutical company dedicated to improving lives through innovative medicines, announced the commercial availability of LUMRYZ. This extended-release sodium oxybate formulation is designed for once-nightly dosing to treat cataplexy, excessive daytime sleepiness (EDS), and idiopathic hypersomnia (IH) in adults